

Matsumoto A, Ichikawa T, Nakao K, Miyaaki H, Hirano K, Fujimoto M, Akiyama M, Miura S, Ozawa E, Shibata H, Takeshita S, Yamasaki H, Ikeda M, <u>Kato N</u> , and Eguchi K.	Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway.	Journal of Gastroenterology	44	856-863	2009
Yano M, Ikeda M, Abe K, Kawai Y, Kuroki M, Mori K, Dansako H, Ariumi Y, Ohkoshi S, Aoyagi Y, and <u>Kato N</u> .	Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase.	Hepatology	50	678-688	2009
Ikeda M, Mori K, Ariumi Y, Dansako H, and <u>Kato N</u> .	Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon- α .	FEBS Letters	583	1434-1438	2009
Dansako H, Ikeda M, Ariumi Y, Wakita T, and <u>Kato N</u> .	Double-stranded RNA-induced interferon-beta and inflammatory cytokine production modulated by hepatitis C virus serine proteases derived from patients with hepatic diseases.	Archives of Virology	154	801-810	2009
Bender H, Wiesinger MY, Nordhoff C, Schoenherr C, Haan C, Ludwig S, Weiskirchen R, and <u>Kato N</u> ,	Interleukin-27 displays interferon γ -like functions in human hepatoma cells and hepatocytes.	Hepatology	50	585-591	2009
Kawai Y, Ikeda M, Abe K, Yano M, Ariumi Y, Dansako H, Yamamoto K, and <u>Kato N</u> .	Development of an HCV relapse model using genome-length HCV RNA harboring cells possessing the IFN- α -resistance phenotype.	Hepatology Research	39	898-909	2009

Vollmer S, Kappler V, Kaczor J, Flügel D, Rolvering C, <u>Kato N</u> , Kietzmann T, Behrmann I, and Haan C.	Hypoxia-inducible factor 1 α is upregulated by Oncostatin M and participates in Oncostatin M signaling.	Hepatology	50	253-260	2009
Nishimura G, Ikeda M, Mori K, Nakazawa T, Ariumi Y, Dansako H, and <u>Kato N</u> .	Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents.	Antiviral Research	82	42-50	2009
Kasai D, Adachi T, Deng L, Nagano-Fujii M, Sada K, Ikeda M, <u>Kato N</u> , Ide Y, Shoji I, and Hotta H.	HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters.	Journal of Hepatology	50	883-894	2009
M. Satoh, M. Saito, K. Tanaka, S. Iwanaga, Salem Nagla Elwy Salem Ali, T. Seki, S. Okada, M. Kohara, S. Harada, C. Kai, and K. Tsukiyama-Kohara.	Evaluation of a recombinant measles virus expressing hepatitis C virus envelope proteins by infection of human PBL-NOD/Scid/Jak3null mouse.	Comp. Immunol. Microbiol. Infect. Dis.	(in press.)		
Y. Amako, K. Tsukiyama-Kohara, A. Katsume, Y. Hirata, S. Sekiguchi, Y. Tobita, Y. Hayashi, T. Hishima, N. Funata, H. Yonekawa, and M. Kohara.	Pathogenesis of hepatitis C virus infection in <i>Tupaia belangeri</i> . [Selected in "Spotlight"]	J. Virology	84	303-311	2010
T. Nishimura, M. Kohara, K. Izumi, Y. Kasama, Y. Hirata, Y. Huang, M. Shuda, C. Mukaidani, T. Takano, Y. Tokunaga, H. Nuriya, M. Satoh, M. Saito, C. Kai and K. Tsukiyama-Kohara.	HEPATITIS C VIRUS IMPAIRS P53 VIA PERSISTENT OVER-EXPRESSION OF 3 β -HYDROXYSTEROL Δ 24-REDUCTASE	J. Biol. Chem.	284	36442-36452	2009

K. Saitou, K. Mizumoto, T. Nishimura, C. Kai and K. Tsukiyama-Kohara.	Hepatitis C virus core protein facilitates the degradation of Ku70 and reduces DNA-PK activity in hepatocytes.	Virus Research	144	266-271.	2009
K. Machida, K. Tsukiyama-Kohara, S. Sekiguch, E. Seike, S. Tone, Y. Hayashi, Y. Tobita, Y. Kasama, M. Shimizu, H. Takahashi, C. Taya, H. Yonekawa, N. Tanaka, and M. Kohara.	Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins.	Gastroenterology	137	285-296.	2009
Y. Inoue, K. Tsukiyama-Kohara, M. Yoneda, H. Sato, and C. Kai.	Inhibition of host protein synthesis in B95a cells infected with the HL strain of measles virus.	Comp. Immunol. Microbiol. Infect. Dis.	32	29-41	2009
小原恭子・町田圭吾・ 小原道法	「C型肝炎ウイルスと Bリンパ腫」	「感染・炎症・免疫」	第39巻 第2号,	61-63	2009
Ishikawa T, Banas A, Hagiwara K, Iwaguro H, Ochiya T.	Stem Cells for Hepatic Regeneration: the Role of Adipose Tissue derived Mesenchymal Stem Cells.	Curr Stem Cell Res Ther	(in press.)		
Ochiya T., Yamamoto Y., Banas A.	Commitment of stem cells into functional hepatocytes.	Differentiation	(in press.)		
Song X, Guo Y, Duo S, Che J, Wu C, Ochiya T, Ding M, Deng H.	A Mouse Model of Inducible Liver Injury Caused by Tet-on Regulated Urokinase for Studies of Hepatocyte Transplantation.	Am J Pathol	26	2705-2712	2009
Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M, Kato T, Okochi H, Ochiya T.	Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure.	J Gastroenterol Hepatol,	24	70-77	2009

Kosaka N, Sakamoto H, Terada M, Ochiya T.	Pleiotropic function of FGF-4: Its role in development and stem cells.	Dev Dyn,	238	265-276	2009
Sugiyama, K, Suzuki, K, Nakazawa, T, Funami, K, Hishiki, T, Ogawa, K, Saito, S, Shimotohno, K.W, Suzuki, T, Shimizu, Y, Tobita, R, Hijikata, M. Takaku, H, Shimotohno, K.	Genetic Analysis of Hepatitis C Virus with Defective Genome and Its Infectivity in Vitro	J. Virol.	83	6922-6928	2009
Takai A, Toyoshima T, Uemura M, Kitawaki Y, Marusawa H, Hiai H, Yamada S, Okazaki IM, Honjo T, Chiba T, Kinoshita K	A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations.	Oncogene	28	469-478	2009
Wada M, Marusawa H, Yamada R, Nasu A, Osaki Y, Kudo M, Nabeshima M, Fukuda Y, Chiba T, Matsuda F	Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.	J Viral Hepat	16	388-396	2009
Ikeuchi K, Marusawa H, Fujiwara M, Matsumoto Y, Endo Y, Watanabe T, Iwai A, Sakai Y, Takahashi R, ChibaT	Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers.	Int J Cancer	125	2029-2035	2009
Endo Y, Marusawa H, Chiba T	Activation-induced cytidine deaminase links inflammation to carcinogenesis.	J Gastroenterology	(in press)		2010

研究成果の刊行物・別刷り

Review

Hepatitis C virus utilizes lipid droplet for production of infectious virus

By Kazuya OGAWA,*¹ Takayuki HISHIKI,*¹ Yuko SHIMIZU,*¹ Kenji FUNAMI,*¹ Kazuo SUGIYAMA,*²
Yusuke MIYANARI*³ and Kunitada SHIMOTOHNO*^{1,3,4,†}

(Communicated by Takao SEKIYA, M.J.A.)

Abstract: Hepatitis C virus (HCV) establishes a persistent infection and causes chronic hepatitis. Chronic hepatitis patients often develop hepatic cirrhosis and progress to liver cancer. The development of this pathological condition is linked to the persistent infection of the virus. In other words, viral replication/multiplication may contribute to disease pathology. Accumulating clinical studies suggest that HCV infection alters lipid metabolism, and thus causes fatty liver. It has been reported that this abnormal metabolism exacerbates hepatic diseases. Recently, we revealed that lipid droplets play a key role in HCV replication. Understanding the molecular mechanism of HCV replication will help elucidate the pathogenic mechanism and develop preventive measures that inhibit disease manifestation by blocking persistent infection. In this review, we outline recent findings on the function of lipid droplets in the HCV replication cycle and describe the relationship between the development of liver diseases and virus replication.

Keywords: hepatitis C virus, lipid droplet, replication, liver disease, VLDL, apolipoprotein

Introduction

Patients infected with hepatitis C virus (HCV) develop acute hepatitis. While 20% of acute hepatitis patients eliminate the virus and recover from the infection, the remaining infectants maintain subclinical state or develop chronic hepatitis as a result of persistent infection. About one-fourth of chronic hepatitis patients progress to hepatic cirrhosis, and half of hepatic cirrhosis patients develop hepatocellular carcinoma (HCC). Many patients with hepatic cirrhosis caused by HCV infection die from the exacerbation of the disease and from HCC. An estimated 15–20% of HCV-infected patients succumb to these hepatic diseases.

Interferon and ribavirin combination therapy is

an effective treatment for chronic hepatitis C. Approximately half of patients who complete this therapy eliminate the virus and, therefore, will not develop hepatic disorders thereafter. Generally, it is thought to be difficult to eliminate persistently or latently infected viruses from host. However, in case of HCV, interferon and ribavirin combination therapy can eliminate HCV in half of infected patients, suggesting that HCV infection is more curable with anti-HCV drugs as compared to other persistently infecting viruses. Because persistent virus replication is one of the causes of chronic diseases, a better understanding of the mechanisms of HCV replication, and modification of host cell proliferation by viral infection, will help elucidate the molecular pathogenic mechanism of the disease.

HCV genome and viral proteins

HCV is classified in the *Hepacivirus* genus of the *Flaviviridae* family. Viruses of the *Flaviviridae* family have the positive-sense, single-strand RNA genome that is packaged into an enveloped viral particle.¹⁾ All the viral proteins are encoded in the largest reading frame in the genome. Translation from the open reading frame of the HCV genome starts by the

*¹ Research Institute, Chiba Institute of Technology, Chiba, Japan.

*² Center for Integrated Medical Research, Keio University, Tokyo, Japan.

*³ Division of Human Genetics, National Institute of Genetics, Shizuoka, Japan.

*⁴ Professor Emeritus, Kyoto University, Kyoto, Japan.

† Correspondence should be addressed: K. Shimotohno, Research Institute, Chiba Institute of Technology, 2-17-1 Tsuda-uma, Narashino, Chiba, 275-0016, Japan (e-mail: kunitada.shimotohno@it-chiba.ac.jp).




Fig. 1. Structure of the HCV genome and the proteins produced by the genome. The HCV genome (upper panel) consists of a positive-sense RNA strand comprising about 10,000 nucleotides. Virus proteins are first produced as a precursor protein encoded in the largest open reading frame that comprises about 90% of the entire genome, then processed by cellular signal protease(s) followed by two virus proteases which are encoded by NS2-NS3, and NS3, respectively. 5' one-thirds of the open reading frame encodes proteins for virus particle and the rest encodes non-structural virus proteins that function in virus-infected cells (lower panel).

mechanism using internal ribosome entry site (IRES) to produce a precursor poly-protein for viral proteins.²⁾ The precursor poly-protein is subsequently cleaved by a cellular signal peptidase and viral peptidases to produce about 10 different viral proteins.^{3),4)} Some proteins receive further modification such as glycosylation or phosphorylation to become functionally matured forms. From the N-terminus of the reading frame, Core, envelope1 (E1), envelope2 (E2), p7, non-structural 2 (NS2), NS3, NS4A, NS4B, NS5A and NS5B are produced in this order (Fig. 1). Viral proteins are divided into two categories: structural proteins and non-structural (NS) proteins. The structural proteins compose the virus particle, while the NS proteins function only inside the infected cell and are not packaged in the virion. The HCV structural proteins include the Core, envelope-1 (E1), and -2 (E2) proteins. The remaining NS proteins have unique functions. One important function of the NS proteins is to construct a stage for viral-genome replication and mRNA synthesis by forming a viral replication complex. This replication complex is a specialized structure protected by a cellular membrane that is induced and built by the virus infection. In addition, another type of NS protein complex is thought to contribute to virus particle assembly.

HCV replicates in the cytoplasm of infected cells (Fig. 2). Current models propose that the virus infects a cell by binding to a cell surface receptor, after which the virus particle is endocytosed into the cytoplasm by clathrin-mediated endocytosis. To date, several candidate proteins including virus receptor(s)




Fig. 2. HCV replication cycle. Since the detailed molecular mechanism of HCV infection/multiplication is yet to be clarified, this figure is drawn as a general view of replication of viruses in *Flaviviridae*, in which HCV is classified. In cells being established virus entry, most of the events for virus replication are conducted in cytoplasm.

have been identified as host factors involved in this process. It seems that the LDL receptor and the scavenger receptor class B type I function in the initial stage of HCV infection, after which the HCV particles interact with the tetraspanin CD81 and the tight-junction protein claudin-1 to establish clathrin dependent internalization.⁵⁾⁻¹²⁾ However, the function of these proteins—from the moment the virus and target cell make contact until infection is established—is not fully understood.

The viral genome replicates in a peculiar membranous structure that is sensitive to detergent around the endoplasmic reticulum¹³⁾⁻¹⁶⁾

For most RNA viruses, the viral genome replicates in the environment associating with membrane components of the host cell. It is expected that HCV genome replication also undergoes a process similar to other RNA viruses. While developing the *in vitro* infection and replication system of HCV, the HCV subgenomic replicon, which lacks the coding region for structural proteins but carries a drug-resistant marker, is established.¹⁷⁾ Since this replicon can replicate autonomously, cell lines bearing the subgenomic replicon can be selected by selectable marker for *neomycin*. Electron microscopic observation revealed that such cells have an unusual membrane structure and that part of the endoplasmic reticulum (ER) membrane is notably deformed.¹³⁾ This membranous structure has a complicated shape as well as a botryoidal structure in some cases and is also seen in liver specimen from a HCV infected individual.




Fig. 3. Altered membranous structure observed in HCV genome replicating cells, in which synthesis of the positive as well as the negative HCV genome is conducted. (A) Electron micrographs of the generation of complex membranous structures (called membranous web) around the ER in HCV genome-replicating cells. The web structure is highlighted by the red circle. (The web image was from Gosert, R *et al.* (2003) *J. Virol.* **77**, 5487 with permission). (B) Diagram of the distribution of NPC (non-structural proteins complex) and RC (replication complex) around the ER membrane. HCV-genome replicating cells treated with digitonin, a detergent that permeabilizes the plasma membrane but does not affect other membranes (e.g., ER-lumen and nuclear membrane)—were analyzed for virus proteins as well as HCV RNA synthesizing activity after incubation of exogenously added protease K. The majority of NS proteins were found to be sensitive to the hydrolysis: only a small portion of NS proteins were found to be resistant to the digestion because of the membrane's protection. Further, the NS protein complex protected by membranous fraction is fully active to synthesize HCV RNA. From this result the NS protein complex exposed to outside of cytoplasm (NPC) and the NS protein complex surrounded with membrane structure (RC) are distinguished and found to have different functions (see text for details).

This structure is called “a membranous web” and is unique to HCV genome bearing cells. Under the labeling condition of *de novo* synthesized RNA, viral-RNA synthesis could be shown to occur around this membranous web.¹⁵⁾ Biochemical analysis of HCV genome-bearing cells was carried out by treating with digitonin, which partially destroys plasma membrane of cells and thus makes cells accessible by exogenous nucleases or proteases present in certain buffer. Through this work the following results were obtained:¹⁴⁾ (1) Surfactants including NP-40 destroyed the replication function of the membranous web; (2) Micrococcal nuclease treatment, under a condition that digests ribosomal RNA completely, did not destroy HCV RNA. However, HCV RNA was immediately destroyed when nuclease treatment was performed in the presence of NP-40, suggesting that viral RNA is protected by membrane components; (3) When digitonin-treated cells were treated

with protease K, most viral proteins were hydrolyzed, but about one-tenth or less of the viral proteins remained without being degraded. However, when the protease digestion was performed in the presence of NP-40, the HCV proteins were no longer resistant to protease digestion. This observation indicates that a small portion of the viral proteins is also protected by membrane structures; (4) When digitonin-treated cells were digested with a protease without surfactants, viral RNA synthesis was not affected even when most viral proteins had disappeared. These results suggest that HCV RNA (both positive and negative strands) is synthesized in a membrane-protected complex where only a small portion of the total HCV proteins in cells is present (Fig. 3).¹⁴⁾ Furthermore, the analyses indicate the presence of a protease-sensitive viral protein complex that is not protected by the membranous component in the outer side of the replication complex. It is presumed that

the protease-sensitive complex is directly exposed to the cytoplasm without the protection of the membranous component. Hereinafter, the complex involving viral-genome replication is referred to as the "replication complex" (RC). The complexes consist of HCV RNA and about 10% of the total viral NS proteins in the host cell (data not shown). The other complex that is retained on the membrane structure but directly exposed to the cytoplasmic environment is referred to as the "non-structural protein complex" (NPC). The function of the NPC is not fully understood. Although detailed analyses are still in progress, it is presumed that NPC plays a role in the assembly process of virus particles (see below). A previous study has reported that one of these viral proteins, NS4B, is capable of changing the membrane structure by acting on the ER membrane.¹³⁾

Cytoplasmic lipid droplets play a key role in the production of infectious HCV particles¹⁸⁾

As mentioned earlier, most HCV proteins localize around the ER membrane in cells that autonomously replicate the HCV genome. In addition, it has been shown that the Core, a structural HCV protein, associates with lipid droplets when it is singularly expressed.¹⁹⁾ It has also been shown that a small portion of NS5A localizes to lipid droplets when NS5A is singularly expressed.²⁰⁾ What is the relationship between the intracellular location of viral proteins, particularly the association of Core and NS5A with the lipid droplet, and viral replication? To understand this phenomenon, we also analyzed the role of Core association with the lipid droplet in virus reproduction using a cell-culture system that produces an infectious virus.¹⁸⁾

When infectious clone JFH1 of HCV genomic RNA is introduced into HuH7 cells (a human liver cancer-derived cell line), genome replication begins and virus particles are produced.²¹⁾ Analysis of the buoyant density of virus particles determined by a sucrose density-gradient centrifugation method indicates the presence of two types of HCV. Most viral particles were detected in a fraction of 1.15 g/ml density, but these particles were not infectious to HuH7 cells. On the other hand, a small amount of infectious virus particles was detected in a 1.12 g/ml density fraction (Fig. 4). In the HCV-replicating cells, the core protein was found to localize around lipid droplets similar to a previous report that identified it via an experiment on the solitary expression of Core pro-




Fig. 4. Characteristics and infectivity of virus particles produced into the culture supernatant. The characteristics of virus particles released from HCV(JFH1^{wild})-replicating cells (left) or cells replicating a mutated virus, JFH1^{AAA999}, encoding proteins that cannot associate with lipid droplets (right) were analyzed by the sucrose density gradient centrifugation method. Dotted, red, and blue lines indicate the amount of virus particles measured by the amount of viral core protein, infectivity and viral RNA, respectively. Buoyant density of sucrose is indicated.

teins in cells.¹⁹⁾ In addition, many of the NS proteins (NS3–NS5B) were co-localized to the ER as previously reported. However, detailed examination revealed that the NS proteins localized around the lipid droplets as well as ER.¹⁸⁾ HCV RNA could also be detected around the lipid droplets. The fraction containing lipid droplets, partially purified by floating centrifugation method, was capable of supporting HCV RNA synthesis. Furthermore, the surrounding environment of the lipid droplets in HCV replicating cells is rich in membrane-like structure (see below). This accumulation of membranous structures around the lipid droplet is unique to the infected cells and is not observed in uninfected control cells.

Core proteins promote the localization of NS proteins to lipid droplets¹⁸⁾

In cells bearing the defective HCV genome not expressing the core protein, the NS proteins were mainly localized on the ER and were not seen around the lipid droplet. However, in cells producing the infectious virus, the NS proteins were localized to both lipid droplets and the ER membrane. The Core and other structural proteins (E2), co-localized to lipid droplets. It is worth noting that the Core promotes the localization of the NS proteins to lipid droplets. This was found using the defective HCV genome




Fig. 5. Membranous structures are frequently observed around the lipid droplets in JFH1-bearing cells. Electron micrographs of the lipid droplets and the surrounding area are shown. These show different images of lipid droplets in cells; a to c, lipid droplets in control Huh-7 cells, and d to f, those in JFH1 bearing Huh7 cells. Arrows indicate enriched membrane structure around the lipid droplet. Arrowhead shows rough ER membrane-like structure attached to the lipid droplet (The data was from Miyanari *et al.* (2007) *Nat. Cell Biol.* 9, 1089–1097).

that does not express the Core. When this mutant genome was expressed, NS5A localized to the ER but not to the lipid droplet. However, when the Core was provided exogenously into the cells, both NS5A and the Core were co-localized to the lipid droplets. Association of other HCV NS proteins with the lipid droplets was also observed by Core dependent manner. This suggests that the Core recruits NS proteins to the lipid droplets, although the mechanism for this association in the presence of Core is unclear.

HCV proteins are arranged in order around lipid droplets in laminae according to protein type

When HCV Core-dependent association of viral NS proteins to the lipid droplets was examined by confocal light and electron microscopy, the Core was shown to be directly localized on the surface of the lipid droplets. However, NS5A was mainly observed in the membranous structure that surrounds the Core-coated lipid droplets.¹⁸⁾ This membrane structure is not of the lipid droplet. More specifically, the Core could be seen as a lamina surrounding the lipid droplet, and the membranous components that are rich in NS proteins surrounded the Core-coated

lipid droplets. While examining intracellular localization and behavior of the Core-coated lipid droplets, majority of Core coated-lipid droplets were found to reside near the ER around the nuclear membrane (data not shown).

Abnormal membrane structures are enriched around lipid droplets in HCV-producing cells

Regarding generation of lipid droplet, several mechanisms have been proposed.^{22),23)} One mechanism is that ER accumulates neutral fat, mainly triglycerides and cholesterol ester, in the space of the membrane bilayer. Increasing the lipid contents increases the mass of the body and the lipid droplet covered with ER-derived membrane buds from the ER.²²⁾ The membrane structure of the lipid droplet is, thus, monolayer. Lipid droplet-specific proteins (such as TAP: TIP-47, ADRP and Perilipin) associate with the monolayer membrane of the lipid droplet. This typical structure of the lipid droplet can be seen in human liver cancer-derived cell line, HuH7 (Fig. 5). However, in HuH7 cells where the infectious HCV genome could replicate and produce virus particles, a part of surface of the lipid droplets were often seen to be covered with several layers of membrane (Fig. 5). Moreover, complicated membranous structures accumulated around the lipid droplets. Although the origin of these membrane structures is unknown, it is assumed that they are derived from ER membranes because the Core-coated lipid droplets are frequently observed around the ER. The ER membranes are also rich in NPC and RC of HCV as shown in the graphic of Fig. 6(A).

Functional analysis of lipid droplets in virus production using the mutated viral genomes

How does the association of viral proteins around the lipid droplets affect virus production? Previously, the domain of the Core to interact with the lipid droplet is disclosed.^{24),25)} Mutations of two proline residues to alanine in that region of Core, Core^{1P/AA}, no longer associate with the lipid droplet.²⁵⁾ When the mutated viral genome that produces Core^{PP/AA} is introduced into cells, the Core as well as HCV NS proteins no longer localize around the lipid droplets.¹⁸⁾ This result indicates that the Core, which is able to associate with the lipid droplet, functions to recruit other viral proteins to the lipid droplets. The cells expressing this mutant genome do not produce virus particles in the culture medium. Under




Fig. 6. Model of the association of the Core-coated lipid droplets with NPC- and RC-rich endoplasmic reticulum. Association of Core-coated lipid droplets with RC- and NPC-rich ER in HuH7 cells bearing the infectious HCV genome, JFH1 (A). Association of Core-coated lipid droplets with the lipid droplet was not observed in cells bearing the mutant JFH1. JFH1^{AAA999}, expressing NS5A with mutations in domain-I (B).¹⁸⁾ and in cells bearing the mutant JFH1. JFH1^{CL3B} encoding NS5A with mutations in domain-III (C).²⁸⁾ Green circles represent lipid droplets. The small orange circles around the lipid droplets are the Core. The largest and the smallest circles with a mosaic represent NPC and RC, respectively. The color of NPC and RC indicates the noted mutations in NS5A in these complexes. Note that the NPC- and RC-rich ER lobes with a mutant NS5A (B and C) do not associate with the core-coated lipid droplet. However, as shown in (B) noninfectious virus particles are released into the culture medium, while NPC and RC with mutations in domain-III of NS5A do not produce virus particles, indicating the lack of virus assembly with this mutant. For NPC and RC localization, see the graphic in Fig. 3.

these conditions, virus production may be inhibited due to lack of association of viral proteins with the lipid droplet that is probably a prerequisite for virus production or virus assembly, or, the mutated Core itself is no more able to execute morphogenesis of virus particle.

An experiment was performed to examine whether or not the association of Core and HCV non-structural proteins to the lipid droplet is essential to virus particle formation.¹⁸⁾ For this purpose the HCV genome with mutation in an NS protein was constructed. NS5A was selected for introducing the mutation among other non-structural proteins as NS5A associates with the lipid droplets more fre-




Fig. 7. Structure of the HCV NS5A protein and mutant NS5A used for the analysis described in this paper.^{18),28)} D-1- D-3 indicates domain-I - domain-III.

quently than other NS proteins and, thus, is thought to play a proactive role in lipid droplet association with other NS proteins. As shown in Fig. 7, NS5A of HCV-1b genotype is a protein with 466-amino-acid residues that can be divided into three domains (domain-I, -II, and -III from the N-terminus). Mutations were introduced into domain-I using alanine-scanning mutagenesis. NS5A mutants that are not severely interfered with genome replication, but fail to associate with lipid droplet were selected among the mutants. By doing so, NS5A mutant in which amino acid residue, APK, of 99-101th or, PPT, of 102-104th, was converted to 3 consecutive alanine residues. When the viral RNA genomes encoding one of these NS5A mutants were introduced into cells and virus production to culture medium was examined, only noninfectious virus particles with 1.15 g/ml buoyant density were produced (Fig. 4).¹⁸⁾

This result confirmed the importance of the lipid droplet for production of "infectious" virus particle. It is likely that infectious virus production requires aggregation of NPC- and RC-rich structures derived from the ER membrane around the lipid droplets. Cells with these structures produced both infectious and noninfectious particles. However, cells bearing the viral genome with mutations in NS5A that failed to associate with the Core-coated lipid droplet produced virus particles that lacked infectivity. Thus, it is likely that lipid droplets play a key role in generating infectious viral particles. Meanwhile, mutants with deletions or point mutations in domain-III in the C-terminus of NS5A had no defect in genome replication but were unable to associate with Core-coated lipid. Neither infectious nor noninfectious viral particles were produced from these cells bearing the genome having these mutations.²⁶⁾⁻²⁸⁾

This observation suggests that NS proteins, which constitute NPC around the Core-coated lipid droplet, are involved in the assembly of infectious virus particles.^{18),26)-28)}

Function of lipid droplets in the production of infectious particles

As mentioned earlier, lipid droplet plays an important role in the production of infectious HCV particles. For this role, one could think the following possibilities: (1) the lipid droplet generates an aggregate together with NPC and RC for the production of infectious virus particles, (2) it provides a factor required for infectivity to the virus particles, and (3) it incorporates virus particle into a vesicle transport system of lipid or lipid related materials to export infectious virus outside the cells. The lipid droplets and their surrounding environment including NPC may be utilized for particle formation because virus-like particles are observed around the lipid droplets by electron microscopy.¹⁸⁾ However, as shown in the model (Fig. 6), non-infectious virus particles can be produced even when the HCV NS proteins are not aggregated with lipid droplets. Therefore, lipid droplets seem to be non-essential organelles involved in the assembly of viral particle. Regarding the second possibility, the buoyant density of infectious virus particles was lower than those of noninfectious virus particles by 0.03 g/ml. This suggests that virus particles produced around the Core-coated lipid droplets have a composition of viral protein and nucleic acid different from that of non-infectious particles which are produced from environment other than that produced with association of the Core-coated lipid droplet, to give rise to virus with lighter density. Or, viruses produced from the lipid droplet-associated environment are composed of, or have associated with components with lower density, which is essential for infectivity. The third proposed role of lipid droplets attracts attention to a new function of lipid droplets as a transporting machinery of virus embedded vesicle. It has been known that the LD is surrounded by a monolayer of phospholipids and dynamically moves through the cytoplasm interacting with other organelles, including mitochondria, peroxisomes, endosomes, and the endoplasmic reticulum (ER).²⁹⁾ It is possible that these interactions facilitate the transport of lipids and lipid-associated proteins to other organelles. Thus, it is also possible that these dynamic movements of the lipid droplet facilitate transport of virus particles to where secretion of virus can take place.

A model of production of infectious HCV

When HCV in the blood stream of patients is analyzed by density-gradient centrifugation, virus is observed as a heterogeneous population with different densities.³⁰⁾ The reasons for this heterogeneity may include the association of HCV with blood components, such as lipoprotein and others, rather than differences in the viral protein or nucleic acid composition. It has been shown that HCV associates with lipoproteins including very low-density lipoprotein (VLDL), low density lipoprotein (LDL), and high-density lipoprotein (HDL).³⁰⁾ In addition, the possibility that virus particles associate with antibodies against the virus itself, rheumatoid factor or cryoglobulin has also been reported. However, the significance of these associations with blood components in the HCV replication cycle is still unknown and many questions remain unanswered. It has been suggested that endocytosis of the *Flaviviridae* viruses such as HCV and bovine viral diarrhoeal virus was mediated by low density lipoprotein (LDL) receptors on cultured cells.³¹⁾ Recently, it has been shown that the association with VLDL has an important role in the secretion of virus particles as well as in the acquisition of infectivity.³²⁻³⁴⁾

VLDL is a particle that consists of a hydrophobic core of neutral lipid surrounded by a monolayer of amphipathic phospholipids and free cholesterol in which apolipoproteins reside.³⁵⁾ VLDL synthesis is mediated by the function of microsomal triglyceride transfer protein (MTP), which regulates the association of triglyceride with apolipoproteins B-100 to synthesize VLDL precursor. Cholesterol ester and additional triglyceride complexed with apolipoproteins E are incorporated while the VLDL precursor is simultaneously transformed to the matured form of VLDL. In HCV-producing cells, it is possible that VLDL precursor accumulates in the microenvironment of the lumen of ER where Core-coated lipid droplets associate with ER membranes rich in RC and NPC, which may increase the amount of the precursor VLDL and allow to associate with HCV which is also budded into ER lumen. It is presumed that HCV/VLDL complexes are secreted to outside of the cell via the Golgi pathway. Importance of lipoproteins to infectivity of HCV is suggested by the fact that an inhibitor of MTP suppresses release of




Fig. 8. Model of the predicted role of the Core-coated lipid droplet in the production of infectious HCV. The association of the Core-coated lipid droplet with NPC and RC-rich ER may enhance the interaction of HCV and VLDL. VLDL is generated frequently and enhanced in the micro-environment where lipid droplets associate with the ER. This increased concentration may increase the frequency of the association of HCV and VLDL. HCV/VLDL is released as an infectious particle with a low density, whereas HCV particles that are not associated with VLDL are secreted into the culture medium as noninfectious, dense particles. However, this model does not discriminate the possibility that noninfectious virus particle also associates with or is integrated with some lipoprotein like structure.

infectious virus particle.^{32),33)} In cells treated with MTP, it was observed that despite the suppression of infectious viruses released into culture medium, intracellular infectious virus particles have a slightly higher density than those released into culture medium. Another possibility for the result obtained by MTP inhibitor experiment is that MTP inhibitor may affect production or function of other cellular factor(s) that associates with HCV or regulates production of infectious HCV.

Recently, we found that Apo-E interacted with HCV NS5A (Hishiki *et al.*, unpublished data). More-

over, Apo-E knockdown cells suppressed the production of infectious virus in a culture medium,³⁶⁾ while Apo-A1 knockdown cells did not (Hishiki *et al.*, unpublished data). Taking this data together with others, it is suggested that Apo-E as well as Apo-B are important host factors, at least in part, involved in endowing infectivity to HCV.

A model of infectious virus particle production that reflects our experimental results, which indicate that the association of Core-coated lipid droplets with the ER membrane is important for infectious virus particle production, is shown in Fig. 8. In this model, we hypothesize that the association of lipid droplets with the ER membrane increases the production efficiency of VLDL precursor in micro-environmental space of the lumen. This higher concentration of VLDL precursor may facilitate the association with HCV which is also budded into ER lumen. But it is unclear whether the formation of this complex occurs actively or passively. Since NS5A binds with Apo-B²⁰⁾ as well as Apo-E, it is possible that the NS proteins promote interaction of VLDL with HCV. Alternatively, integration of Apo-E and/or Apo-B to micro-environmental membranous structure where HCV particle buds may also be likely. In this case Apo-B and/or Apo-E should be integrated as a membranous component of HCV membranous structure. Although involvement of VLDL for infectious HCV production was suggested, it remains to be clarified whether or not VLDL itself associates with HCV before virus release to culture medium. There is no direct evidence to show this association in an *in vitro* experiment.

It has been reported that HCV infection is mediated by various cellular receptors and the LDL receptor (LDLR) is one of them.^{31),34)} VLDL or its derivative(s) in the VLDL/HCV complex, or Apo-B and -E in HCV may act as a ligand of LDLR on surface protein of hepatocyte.

Increase in lipid droplets in HCV-infected cells

It has been shown that the lipid droplet is an important cellular organelle that produces infectious HCV.¹⁸⁾ Then, how does HCV infection affect lipid droplets in the cell? As described above, the structure of the membrane monolayer of the lipid droplet is modified in HCV-replicating cells: multilayered membrane structure on the surface of the lipid droplet are observed often and, moreover, lipid droplets are surrounded by an excess membranous structure.

In addition, the amount of lipid droplets increases in HCV-replicating cells.¹⁸⁾ Enhanced production of the lipid droplet seems to be mediated by the expression of Core, which is suggested by the following experiment. When autonomous HCV replicon lacking Core production was expressed in HuH7 cells, no enhanced expression of lipid droplet was observed by confocal microscopy analysis of stained cells with BODIPY 493/503 (Invitrogen), a marker for the lipid droplet. In contrast, cells expressing the full HCV replicon showed substantial enhanced production of lipid droplet. Enhancement of lipid droplet production was also observed by ectopic expression of Core in cells bearing HCV replicon lacking expression of the Core. Therefore, it was concluded that HCV infection increases the amount of lipid droplets and that the Core is required for this increase. The amount of intercellular lipids depends on a balance between lipid synthesis, degradation, and lipid transport to the outside of the cell. The Core enhances lipid synthesis by activating SREBP, a transcription factor necessary for lipid synthesis, as well as by suppressing MTP activity slightly. NS5A is also reported to suppress MTP activity some extent. These roles of Core and NS5A are probably significant for balancing intracellular lipid level in HCV infected cells.

Relationship between abnormal cellular metabolism of lipid in HCV-infected cells and HCV related hepatic disease

Many questions about the molecular basis between infection/replication of HCV and the development of chronic hepatitis, hepatic cirrhosis, and liver cancer remain unsolved. It is believed that chronic hepatitis results from the continuous destruction and regeneration of hepatic cells. It has been suggested that continuous immuno-mediated destruction of liver plays a central role in liver pathogenesis by HCV infection. On the other hand, many HCV-infected patients can experience complicated diabetes due to inhibition of insulin signal transduction and can also experience abnormal metabolism, including increased liver lipid content, because of abnormal lipid accumulation. In addition, these disorders are thought to exacerbate liver diseases.^{37)–39)}

Transgenic mice producing HCV core protein develop steatosis and subsequent liver cancer.⁴⁰⁾ This suggests that abnormal lipid metabolism caused by the HCV core protein can lead to the development of liver cancer at least in mouse model system.

The physiological significance of the mechanism by which the HCV core protein controls lipid metabolism became clear when lipid droplets were shown to be essential in the production of infectious virus particles in infected cells. In other words, HCV requires activation of lipid metabolism in the host cell to produce its progeny efficiently, which is, at least in part, a requisite of abnormal metabolism of lipid that may be linked to subsequent liver diseases in the host.

Conclusions

HCV establishes persistent infection and causes chronic hepatitis, which causes the development of hepatic cirrhosis and liver cancer in some patients. Therefore, it is very important to prevent infection and disease progression. A better understanding of the molecular mechanisms of virus replication would help to establish preventative measures. Recent studies have uncovered a mechanism of HCV replication in which lipid droplets are used to produce infectious virus. This finding may contribute to uncovering the link between HCV infection/replication and liver pathogenesis. A detailed analysis of the mechanism of HCV replication will further increase our understanding of the interaction between the virus and host cell, to explain disease development.

Acknowledgements

This work was supported by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology; by grants-in-aid for the Research for the Future Program from the Japanese Society for the Promotion of Science; and by grants-in-aid for the Program for Promotion of Fundamental Studies in Health Science from the Organization for Pharmaceutical Safety.

References

- 1) Lindenbach, B.D., Thiel, H.J. and Rice, C. (2007) The viruses and their replication. *In* Field's Virology (eds. Knipe, D.M. and Howley, P.M.). Lippincott-Raven, Philadelphia, pp. 1101–1152.
- 2) Tsukiyama-Kohara, K., Iizuka, N., Kohara, M. and Nomoto, A. (1992) Internal ribosome entry site within hepatitis C virus RNA. *J. Virol.* **66**, 1476–1483.
- 3) Grakoui, A., Wychowski, C., Lin, C., Feinstone, S.M. and Rice, C.M. (1993) Expression and identification of hepatitis C virus polyprotein cleavage products. *J. Virol.* **67**, 1385–1395.
- 4) Tanji, Y., Hijikata, M., Hirowatari, Y. and Shimotohno, K. (1994) Hepatitis C virus polyprotein

- processing: kinetics and mutagenic analysis of serine proteinase-dependent cleavage. *J. Virol.* **68**, 8418–8422.
- 5) Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R. *et al.* (1998) Binding of hepatitis C virus to CD81. *Science* **282**, 938–941.
 - 6) Agnello, V., Abel, G., Elfahal, M., Knight, G.B. and Zhang, Q.X. (1999) Hepatitis C virus and other *Flaviviridae* viruses enter cell via low density lipoprotein receptor. *Proc. Natl. Acad. Sci. USA* **96**, 12766–12771.
 - 7) Germin, R., Crance, J.M., Garin, D., Guinnet, J., Lortat-Jacob, H., Ruijgrok, R.W. *et al.* (2002) Cellular glycosaminoglycans and low density lipoproteins receptor are involved in hepatitis C virus adsorption. *J. Med. Virol.* **68**, 206–215.
 - 8) Scarselli, E., Ansuini, H., Ceriulo, R., Roccasecca, R.M., Acali, S., Filocamo, G. *et al.* (2002) The human scavenger receptor class B type 1 is a novel candidate receptor for the hepatitis C virus. *EMBO J.* **21**, 5017–5025.
 - 9) Lozach, P.Y., Lortat-Jacob, H., de Lacroix de Lavalette, A., Staropoli, I., Foung, S., Amara, A. *et al.* (2003) DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. *J. Biological Chem.* **279**, 20358–20366.
 - 10) Evans, M.J., von Hahn, T., Tschemme, D.M., Syder, A.J., Panis, M., Wolk, B. *et al.* (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. *Nature* **446**, 801–805.
 - 11) Helle, F. and Dubuisson, J. (2008) Hepatitis C virus entry into host cells. *Cell Mol. Life Sci.* **65**, 100–112.
 - 12) Cocquerel, L., Voisset, C. and Dubuisson, J. (2006) Hepatitis C virus entry: potential receptors and their biological functions. *J. Gen. Virol.* **87**, 1075–1084.
 - 13) Egger, D., Wölk, B., Gosert, R., Bianchi, L., Blum, H.E., Moradpour, D. *et al.* (2002) Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. *J. Virol.* **76**, 5974–5984.
 - 14) Miyanari, Y., Hijikata, M., Yamaji, M., Hosaka, M., Takahashi, H. and Shimotohno, K. (2003) Hepatitis C Virus Non-structural proteins in the probable membranous compartment function in viral genome replication. *J. Biol. Chem.* **278**, 50301–50308.
 - 15) Gosert, R., Egger, D., Lohmann, V., Bartenschlager, R., Blum, H.E., Bienz, K. *et al.* (2003) Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. *J. Virol.* **77**, 5487–5492.
 - 16) Aizaki, H., Lee, K.J., Sung, V.M., Ishiko, H. and Lai, M.M. (2004) Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. *Virology* **324**, 450–461.
 - 17) Lohman, V., Korner, F., Koch, J., Herian, U., Theilmann, L. and Bartenschlager, R. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* **285**, 110–113.
 - 18) Miyanari, Y., Atsuzawa, K., Usuda, N., Watahi, K., Hishiki, T., Zayas, M. *et al.* (2007) The lipid droplet is an important organelle for hepatitis C virus production. *Nat. Cell Biol.* **9**, 1089–1097.
 - 19) Barba, G., Harper, F., Harada, T., Kohara, M., Goulinet, S., Matsuura, Y. *et al.* (1997) Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. *Proc. Natl. Acad. Sci. USA* **94**, 1200–1205.
 - 20) Shi, S.T., Polyak, S.J., Tu, H., Taylor, D.R., Gretchen, D.R. and Lai, M.M. (2002) Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. *Virology* **292**, 198–210.
 - 21) Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamaoto, M., Zhao, Z. *et al.* (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nature Med.* **11**, 791–796.
 - 22) Martin, S. and Parton, R.G. (2006) Lipid droplets: a unified view of a dynamic organelle. *Nat. Rev. Mol. Cell Biol.* **7**, 373–378.
 - 23) Olofsson, S.O., Boström, P., Andersson, L., Rutberg, M., Pernau, J. and Borén, J. (2008) Lipid droplets as dynamic organelles connecting storage and efflux of lipids. *Biochim. Biophys. Acta*, doi:10.1016/j.bbaliip.2008.08.001.
 - 24) Hope, R.G. and McLauchlan, J. (2000) Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein. *J. Gen. Virol.* **81**, 1913–1925.
 - 25) Hope, R.G., Murphy, D.J. and McLauchlan, J. (2002) The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteins. *J. Biol. Chem.* **277**, 4261–4270.
 - 26) Appel, N., Zayas, M., Miller, S., Krijnse-Locker, J., Schaller, T., Friebe, P. *et al.* (2008) Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. *PLoS Pathog.* **4**(3), e1000035.
 - 27) Tellinghuisen, T.L., Foss, K.L. and Treadaway, J. (2008) Regulation of hepatitis C virus production via phosphorylation of the NS5A protein. *PLoS Pathog.* **4**(3), e1000032.
 - 28) Masaki, T., Suzuki, R., Murakami, K., Aizaki, H., Ishii, K., Murayama, A. *et al.* (2008) Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. *J. Virol.* **82**, 7964–7976.
 - 29) Murphy, S., Martin, S. and Parton, R.G. (2008) Lipid droplet-organelle interactions: sharing the fats. *Biochim. Biophys. Acta*. doi:10.1016/j.bbaliip.2008.07.004.
 - 30) Nielsen, S.U., Bassendine, M.F., Burt, A.D., Martin, C., Punccechockchai, W. and Toms, G.L. (2006) Association between hepatitis C virus and very-low-density lipoprotein (LDL)/LDL analyzed in iodixanol density gradients. *J. Virology* **80**, 2418–2428.
 - 31) Agnello, V., Abel, G., Elfahal, M., Knight, G.B. and Zhang, Q.X. (1999) Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. *Proc. Natl. Acad. Sci. USA* **96**, 12766–127671.

- 32) Huang, H., Sun, H., Owen, F., Li, D.M., Chen, W., Gale, Y. *et al.* (2007) Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. *Proc. Natl. Acad. Sci. USA* **104**, 5848–5853.
- 33) Gastaminza, P., Cheng, G., Wieland, S., Zhong, J., Liao, W. and Chisari, F.V. (2008) Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. *J. Virol.* **82**, 2120–2129.
- 34) Molina, S., Castet, V., Fournier-Wirth, C., Pichard-Garcia, L., Avner, R., Harats, D. *et al.* (2007) The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. *J. Hepatol.* **46**, 411–419.
- 35) Fisher, E.A. and Ginsberg, H.N. (2002) Complexity in the secretory pathway: the assembly and secretion of apolipoproteins B-containing lipoproteins. *J. Biol. Chem.* **277**, 17377–17380.
- 36) Chang, K.S., Jiang, J., Cai, Z. and Luo, G. (2007) Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture. *J. Virol.* **81**, 13783–13793.
- 37) Negro, F. (2006) Mechanisms and significance of liver steatosis in hepatitis C virus infection. *World J. Gastroentero.* **12**, 6756–6765.
- 38) Powell, E.E., Jonsson, J.R. and Clouston, A.D. (2005) Steatosis: co-factor in other liver diseases. *Hepatology* **42**, 5–13.
- 39) Pekow, J.R., Bhan, A.K., Zheng, H. and Chung, R.T. (2007) Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. *Cancer* **109**, 2490–2496.
- 40) Moriya, K., Fujie, H., Shintani, Y., Yotsuyanagi, H., Tsutsumi, T., Ishibashi, K. *et al.* (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat. Med.* **4**, 1065–1067.

(Received Apr. 23, 2009; accepted June 12, 2009)



3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV

Hussein Hassan Aly^a, Kunitada Shimotohno^b, Makoto Hijikata^{a,c,*}

^a Laboratory of Human Tumor Viruses, The Institute for Virus Research, Kyoto University, Department of Viral Oncology, 53 Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan

^b Center for Human Metabolomic Systems Biology, Keio University, 35 Shinano-machi, Shinjuku-ku, Tokyo 160-8582, Japan

^c Laboratory of Viral Oncology, Graduate School of Biostudies, Kyoto University, Konoecho, Yoshida, Sakyoku, Kyoto 606-8501, Japan

ARTICLE INFO

Article history:

Received 5 December 2008

Available online 25 December 2008

Keywords:

Hepatitis C virus

Infection

Replication

3D culture

PPAR

Immortalized hepatocytes

Blood-borne HCV

ABSTRACT

Due to the high polymorphism of natural hepatitis C virus (HCV) variants, existing recombinant HCV replication models have failed to be effective in developing effective anti-HCV agents. In the current study, we describe an *in vitro* system that supports the infection and replication of natural HCV from patient blood using an immortalized primary human hepatocyte cell line cultured in a three-dimensional (3D) culture system. Comparison of the gene expression profile of cells cultured in the 3D system to those cultured in the existing 2D system demonstrated an up-regulation of several genes activated by peroxisome proliferator-activated receptor alpha (PPAR α) signaling. Furthermore, using PPAR α agonists and antagonists, we also analyzed the effect of PPAR α signaling on the modulation of HCV replication using this system. The 3D *in vitro* system described in this study provides significant insight into the search for novel anti-HCV strategies that are specific to various strains of HCV.

© 2008 Elsevier Inc. All rights reserved.

Infection with Hepatitis C virus (HCV) is a serious health problem worldwide and leads to high rates of liver cirrhosis and hepatocellular carcinoma [1]. Given that the standard HCV therapy remains insufficient for the successful treatment of many patients [2], the development of more effective and less toxic anti-HCV agents is required. *In vitro* systems like the HCV replicon-bearing cells and the infectious particle-producing JFH1 system, has contributed to the discovery of new targets for anti-HCV therapy. However, these recombinant HCV genomes only proliferate in sub-lines of HuH-7 cells, which do not permit infection or proliferation of blood-borne HCV. Due to the high polymorphism of natural HCV, data from recombinant HCV systems could be evaluated by studying the therapeutic response of a variety of naturally occurring HCVs. However, the current systems available for such study remain insufficient due to the low infection and replication efficiency of the natural HCV strains.

More recently, production and secretion of infectious HCV particles has been reported in two independent three-dimensional (3D) cell culture systems, termed the radial-flow bioreactor (3D/RFB) and the thermoreversible gelatin polymer (3D/TGP) systems. These results were not observed in monolayer cultures [3],

suggesting that hepatocytes cultured in 3D more closely resemble liver cells *in vivo* [4] and thus support HCV proliferation. In addition, analysis of gene expression levels in 3D cultured cells revealed that the newly established immortalized human hepatocyte (HuS-E/2 cells) gene profile was altered to more closely resemble that of human liver tissue when the cells were cultured in 3D/TGP [5].

In the current study, we cultured HuS-E/2 cells in 3D/TGP and demonstrated efficient proliferation of natural HCV. Furthermore, gene expression analysis of these cells demonstrated the activation of the peroxisome proliferators-activated receptor α (PPAR α) signaling pathway, suggesting an important role for this pathway in the replication of natural HCV. Thus, the *in vitro* system described appears to be a useful tool for the study of HCV infection and proliferation as well as for the development of effective anti-viral agents against various natural HCVs.

Materials and methods

Cell culture. Immortalized human hepatocytes (HuS-E/2) and LucNeo#2 replicon cells [6] were cultured as previously described [5,7]. For the 3D-TGP culture system, 1×10^5 HuS-E/2 cells were cultured in 1 ml Mebiol gel (Mebiol Inc., Kanagawa, Japan)/well in 12-well plates. Five hundred microliters of fresh medium was overlaid on the solidified gel, and was changed every 2 days. Cell

* Corresponding author. Address: Laboratory of Human Tumor Viruses, The Institute for Virus, Kyoto University, Department of Viral Oncology, 53 Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan. Fax: +81 75 751 3998.

E-mail address: mhijikata@virus.kyoto-u.ac.jp (M. Hijikata).

extraction from the gel was done at the designated time points according to the manufacturer's protocol.

RNA extraction, reverse transcriptase polymerase chain reaction (RT-PCR) and real-time RT-PCR (Q-PCR). At the designated time points, total cellular RNA was extracted and 1 μg of total RNA was used as a template for RT-PCR and for the quantitative detection of HCV-RNA using real-time RT-PCR (Q-PCR) as previously described [10].

HCV infection experiment. HCV infection experiments were carried out using sera from patients infected with HCV. Infection in 2D culture was undertaken as previously described [5]. For 3D/TGP cultured cells, the gel was solidified, and 50 μl HCV-containing patient serum with a titer of 1×10^6 HCV-RNA/ml was added to the culture and mixed. The culture was continued until the cells were extracted. Following extraction from 3D-TGP, cells were centrifuged and washed three times thoroughly with PBS. RNA was then extracted from the cells as described above. HCV infection into HuS-E/2 cells was also examined in the presence of anti-E2 mouse monoclonal antibody (917) as outlined previously [8].

Treatment of cells with PPAR α signaling agonists and antagonists. Fenofibrate or MK886 (Sigma–Aldrich, USA) were added to the culture medium of HuS-E/2 (2D-HuS-E/2) cells from day 0 of HCV infection; or the culture medium of LucNeo#2 replicon harboring cells. The cells were then cultured to the designated time point.

Microarray analysis. Gene expression profiles of 3D/TGP cultured HuS-E/2 cells were obtained by microarray analysis (3D-Genes Human 25, Toray, Tokyo, Japan) and compared to those of cells cultured in 2D.

Results

3D/TGP cultures enhance HCV proliferation in HuS-E/2 cells

Infection and proliferation of the HCV genotype 1b (HCV-RC5) derived from the serum of patient RC5 in HuS-E/2 cells cultured in 3D/TGP (3D/TGP-HuS-E/2 cells) was investigated and compared with that of HuS-E/2 cells cultured in 2D (2D-HuS-E/2). As outlined in Fig. 1A, the HCV-RNA levels in the 3D/TGP-HuS-E/2 cells were significantly higher at all of the time points examined following infection than in the 2D-HuS-E/2 cells, suggesting that the 3D/TGP system greatly enhances the proliferation of naturally occurring HCV in HuS-E/2 cells. Similar results were also obtained for sera from additional patients (data not shown). To examine whether the infection is viral envelope-receptor mediated, the infection experiments using serum treated with anti-HCV-E2 antibody (α -E2) or with anti-tubulin (negative control) was also performed. Pre-incubation of the serum with α -E2 significantly reduced the total amount of HCV-RNA in the cells upon infection (Fig. 1B). This result suggested that the infection of natural HCV into 3D/TGP-HuS-E/2 cells was HCV-E2-dependent.

Inhibition of natural HCV replication in HuS-E/2 cells by Interferon

In order to test the effects of anti-viral agents on natural HCV replication in 3D/TGP HuS-E/2 cells, 50–100 U/ml of IFN α was added to the medium overlaying the HCV-RC5 infected 3D/TGP-HuS-E/2 cells. The two treatment concentrations resulted in the inhibition of HCV-RNA replication in 3D-HuS-E/2 cells by




Fig. 1. HCV infection into 3D/TGP-HuS-E/2 cells. (A) 3D/TGP significantly enhanced HCV proliferation in HuS-E/2 cells. HCV patient serum was used to infect a similar number of HuS-E/2 cells cultured in 2D (hashed line) or 3D/TGP (solid line) culture for 24 h. Cells were then harvested and lysed at the indicated time points (3–7 days). The quantity of genomic HCV-RNA per 1 μg total RNA was determined by Q-PCR analysis. (B) Anti-E2 antibodies blocked HCV infection. HCV infection was performed as described in panel A in the presence of Anti-E2 specific or anti-tubulin (control) antibodies. (C) IFN α inhibits HCV replication in 3D/TGP-HuS-E/2 cells. HuS-E/2 cells were infected with HCV and fresh medium supplemented with or without (Mock), 50 U/ml, or 100 U/ml IFN α overlaid on the gel containing the cells and HCV proliferation measured as described above.




Fig. 2. RT-PCR analysis of the expression of genes identified by microarray. The PPAR α regulated genes were increased in 3D/TGP-HuS-E/2 cells (3D-TGP) and their expression levels measured by RT-PCR. 2D represents RNA samples from 2D-HuS-E/2 cells. Twenty cycles of amplification were undertaken for the RT-PCR analysis. GAPDH expression served as an internal control. Abbreviations: FABP3, fatty acid binding proteins 3; FABP4, fatty acid binding proteins 4; ACOX2, acyl-coenzyme A oxidase 2; APOD, apolipoprotein D; AQP7, aquaporin 7; FADS2, fatty acid desaturase 2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

approximately 50–60% and almost completely, respectively, when compared to the replication in cells receiving mock treatment (Fig. 1C). These results demonstrate that the IFN α treatment was effective on HCV derived from RC5 and that 3D/TGP-HuS-E/2 cells may be useful for the screening of anti-HCV drugs for the treatment of natural HCV.

Increased activation of the PPAR α signaling pathway in 3D cultured HuS-E/2 cells

Given that 3D/TGP-HuS-E/2 cells demonstrated enhanced proliferation of natural HCV, the gene expression profiles of these cells was compared with that of cells cultured under normal 2D conditions using microarray analysis in order to identify the factors required for the enhanced proliferation. Among the 24,268 genes compared in this analysis, 212 genes demonstrated a greater than four folds index increase in expression in 3D/TGP than standard cultured cells. Cell signaling pathway analysis of these 212 genes showed that six genes, including fatty acid binding proteins 4 and 3 (FABP4 and 3), apolipoprotein D (APOD), aquaporin 7 (AQP7), acyl-coenzyme A oxidase 2 (ACOX2), and fatty acid desaturase 2 (FADS2), were targets of PPAR α signaling [9–12]. The increased expression of these genes in the 3D/TGP-HuS-E/2 cells was further confirmed by RT-PCR analysis (Fig. 2). Given that PPAR α is an essential factor for normal hepatocyte function [13], these results indicate that 3D/TGP culture enhances the hepatocyte-specific characteristics of HuS-E/2 cells.




Fig. 3. The effects of PPAR α agonists and antagonists on natural HCV proliferation. (A) HuS-E/2 cells were infected with HCV and fresh medium supplemented with or without (Mock) 2, 10, or 30 μM of fenofibrate overlaid on the cells. (B) Medium supplemented with or without (Mock), 2, 5, or 10 μM of MK886 was overlaid on 2D-HuS-E/2 cells infected with HCV. HCV proliferation following treatment was measured by Q-PCR. (C) Medium supplemented with or without (Mock), 10 μM of MK886 was overlaid on 3D/TGP-HuS-E/2 cells infected with HCV. HCV proliferation following treatment was measured by Q-PCR.

PPAR α signaling affects HCV replication

We next examined the potential role of PPAR α signaling on HCV proliferation by monitoring HCV replication in 2D-HuS-E/2 cells that had been infected with HCV-RC5 and subsequently treated with the PPAR α agonist fenofibrate [14] or the PPAR α antagonist MK886 [14] (Fig. 3B). As outlined in Fig. 3A, a dose-dependent increase in HCV replication was observed in fenofibrate-treated cells. In contrast, a dose-dependent decrease in HCV proliferation was observed in the presence of MK886. Similarly, treatment with MK886 reduced HCV proliferation in 3D/TGP-HuS-E/2 cells (Fig. 3C). The response of HCV proliferation in response to fenofibrate and MK886 treatment was also analyzed in LucNeo#2 cells that contained HCV replicon RNA (LNMH14) derived from the HCV-1b genome (Fig. 4A). Luciferase expression in these cells represented replication of the HCV replicon [6] and, as shown in Fig. 4A, luciferase activity in the cells treated with fenofibrate or MK886 also showed either enhancement or suppression of replicon proliferation, respectively. In addition, the increased HCV replication following fenofibrate treatment was completely abolished when treated with MK886 simultaneously. As MK886 is known to induce apoptosis when administered in high doses [15], the cell viability

was examined using the XTT assay. There were no significant effects on cell viability after treatment with fenofibrate. Although MK886 resulted in a minor reduction in XTT values when high doses (10–15 μ M) were administered, this reduction was not statistically significant when compared to its effect on HCV replication (Fig. 4B). This result suggests that PPAR α signaling is required for HCV replication and that suppression of PPAR α signaling has an anti-HCV effect.

Discussion

In the current study, we demonstrated that immortalized hepatocyte HuS-E/2 cells cultured in 3D/TGP support the infection and replication of natural HCV derived from patient sera. Unlike recombinant HCVs, which have been required to adapt to sublines of HuH-7 cells [16], the population of the natural HCV is fairly polymorphic, demonstrating different responses to a variety of anti-viral agents [17,18]. The 3D/TGP-HuS-E/2 cells have the advantage of being a small-scale 3D cultured cells, which are cultured in 12-well plates at a density of 1×10^5 /well, that allow the study of both viral and cellular events. In the current study, it demonstrated a 2 log increase in susceptibility to natural HCV infection and replication when compared to conventional 2D culture systems. Thus it offers an important advantage in the study of natural HCV infection and replication, and the response of natural HCV to anti-HCV drugs.

As the ability of HuS-E/2 cells to support infection and replication of natural HCV was greatly altered by the culture conditions, it is likely that the culture system described in our study will provide important information in regards to the cellular factors that support the HCV life cycle. The microarray study showed that the expression of some genes related to the PPAR α signaling pathway were upregulated in the 3D cultured HuS-E/2 cells. Using both PPAR α signaling agonists and antagonists, PPAR α signaling was shown to affect infection and proliferation of natural HCV. PPAR α is a ligand-activated transcription factor that is primarily expressed in tissues with high lipid metabolism including the liver, where it functions as one of three major nuclear receptors and is essential for its normal function [19]. Similar to a part of our data, a negative effect on HCV replication was previously observed in the replicon-bearing cells treated with siRNA for PPAR α , with only 50% reduction of HCV-RNA [20]. In this study, even a large dose of PPAR α agonist enhanced natural HCV replication in the 2D-HuS-E/2 cells for three times, despite the 2 logs enhancement of HCV proliferation in 3D/TGP culture. This implies that additional factors activated in 3D/TGP-HuS-E/2 cells may be required for the efficient HCV proliferation. Further analysis of the microarray data may provide us with further information on factors that may prove useful in the development of anti-HCV drugs.

In conclusion, the novel *in vitro* culture system combining TGP and immortalized hepatocytes described in this study demonstrated efficient support of natural HCV infection and replication. This system may be used in future virological studies to define new anti-HCV strategies. It may also prove useful for the specific design of effective individual therapy according to patient-specific strains.

Acknowledgments

This work was supported by Grants-in-Aid from the Ministry of Health, Labor and Welfare of Japan; and for scientific research from Ministry of Education, Sports, Culture, and Technology of Japan.

References

- [1] Z. Younossi, J. Kallman, J. Kincaid, The effects of HCV infection and management on health-related quality of life, *Hepatology* 45 (2007) 806–816.




Fig. 4. The effects of PPAR α agonists and antagonists on the replication of HCV subgenomic replicons. (A) LucNeo#2 cells containing a HCV subgenomic replicon termed LNMH14, were mock treated or treated with fenofibrate, MK886, or a combination of both fenofibrate and MK886 at the indicated concentrations for 2 days. Luciferase activity derived from the replicon was then measured as an indicator of HCV replication [7]. (B) Following treatment with fenofibrate and MK886, LucNeo#2 cells were cultured for 2 days and cell viability measured using the XTT assay (Roche, Mannheim, Germany).